January 8, 2026 Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
December 8, 2025 Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
August 5, 2025 Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
May 12, 2025 Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
May 5, 2025 Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
April 23, 2025 Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
April 3, 2025 Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
March 26, 2025 Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
October 22, 2024 Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT
June 7, 2024 Epicrispr Biotechnologies to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress
May 23, 2024 Epicrispr Biotechnologies to Participate in Fireside Chat at Stifel’s Genetic Medicines Forum
April 23, 2024 Epicrispr Biotechnologies Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
